Presentation is loading. Please wait.

Presentation is loading. Please wait.

Oral Anticoagulation and Preventing Stent Thrombosis

Published byAndrew Martin Modified over 6 years ago

Similar presentations

Presentation on theme: "Oral Anticoagulation and Preventing Stent Thrombosis"— Presentation transcript:

1 Oral Anticoagulation and Preventing Stent Thrombosis

2 Unadjusted Kaplan-Meier Survival Curves for STEMI vs NSTEMI

3

4

5 ATLAS ACS 2—TIMI 51: Rivaroxaban

6

7 All-cause mortality, non-fatal MI, non-fatal stroke, and severe recurrent ischemia (%); all patients received ASA +/- clopidogrel

8 Primary Safety Endpoint: Major and CRNM bleeding at 6 months

9

10 Stent Thrombosis: ATLAS ACS 2—TIMI 51 and APPRAISE-2

11 The Thrombin Paradox

12 ATLAS ACS 2—TIMI 51: Mortality

13 Abbreviations ACE = angiotensin-converting enzyme ACS = acute coronary syndrome ADP = adenosine diphosphate AF = atrial fibrillation APPRAISE-2 = Apixaban for Prevention of Acute Ischemic Events 2 aPC = activated protein C ASA = aspirin ATLAS ACS 2—TIMI 51 = Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects with Acute Coronary Syndrome–Thrombolysis in Myocardial Infarction 51 BID = twice daily CI = confidence interval CRNM = clinically relevant, non-major CURE = Clopidogrel in Unstable Angina to Prevent Recurrent Events DAPT = dual antiplatelet therapy ESTEEM = Efficacy and Safety of the Oral Direct Thrombin Inhibitor Ximelagatran in Patients With Recent Myocardial Damage HR = hazard ratio i = inactive ISTH = International Society of Thrombosis and Haemostasis

14 Abbreviations (cont) MI = myocardial infarction NSTE-ACS = non-ST segment elevation acute coronary syndrome NSTEMI = non ST-segment elevation myocardial infarction PAR-1 = protease-activated receptor QD = once daily RE-DEEM = Randomized Dabigatran Etexilate Dose Finding Study in Patients With Acute Coronary Syndromes Post Index Event With Additional Risk Factors for Cardiovascular Complications Also Receiving Aspirin and Clopidogrel: Multi-centre, Prospective, Placebo Controlled, Cohort Dose Escalation Study ROCKET-AF = Rivaroxaban With Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Patients With Non-Valvular Atrial Fibrillation RUBY-1 = Study Evaluating Safety, Tolerability and Efficacy of YM150 in Subjects With Acute Coronary Syndromes STEMI = ST-segment elevation myocardial infarction TF = tissue factor

Download ppt "Oral Anticoagulation and Preventing Stent Thrombosis"

Similar presentations

August 30, 2009 at CET. Ticagrelor compared with clopidogrel in patients with acute coronary syndromes – the PLATO trial.

August 30, 2009 at CET. Ticagrelor compared with clopidogrel in patients with acute coronary syndromes – the PLATO trial.
The Changing Landscape of Anticoagulation William D. Cahoon, Jr., PharmD, BCPS Cardiology Clinical Pharmacist VCU Health System April 12, 2012.

The Changing Landscape of Anticoagulation William D. Cahoon, Jr., PharmD, BCPS Cardiology Clinical Pharmacist VCU Health System April 12, 2012.
Standard Medical Therapy TRA 40 mg + 2.5 mg/d TRA 40 mg + 2.5 mg/d Placebo EP:CV Death/MI/stroke/hosp for RI/urgent coronary revasc. 1  EP:CV Death/MI/stroke/hosp.

Standard Medical Therapy TRA 40 mg mg/d TRA 40 mg mg/d Placebo EP:CV Death/MI/stroke/hosp for RI/urgent coronary revasc. 1  EP:CV Death/MI/stroke/hosp.
North of Tyne anti-platelet guidelines: use in primary care Jane S Skinner Consultant Community Cardiologist.

North of Tyne anti-platelet guidelines: use in primary care Jane S Skinner Consultant Community Cardiologist.
Gregg W. Stone MD for the ACUITY Investigators Gregg W. Stone MD for the ACUITY Investigators A Prospective, Randomized Trial of Bivalirudin in Acute Coronary.

Gregg W. Stone MD for the ACUITY Investigators Gregg W. Stone MD for the ACUITY Investigators A Prospective, Randomized Trial of Bivalirudin in Acute Coronary.
Novel antithrombotic agents in acute coronary syndromes: better or worse than P2Y12 inhibitors Giuseppe Biondi Zoccai Sapienza Università di Roma

Novel antithrombotic agents in acute coronary syndromes: better or worse than P2Y12 inhibitors Giuseppe Biondi Zoccai Sapienza Università di Roma
Giuseppe Biondi-Zoccai Division of Cardiology, University of Turin, Turin, Italy.

Giuseppe Biondi-Zoccai Division of Cardiology, University of Turin, Turin, Italy.
Luigi Oltrona Visconti Divisione di Cardiologia IRCCS Fondazione Policlinico S. Matteo Pavia Sindromi coronariche acute nei pazienti con fibrillazione.

Luigi Oltrona Visconti Divisione di Cardiologia IRCCS Fondazione Policlinico S. Matteo Pavia Sindromi coronariche acute nei pazienti con fibrillazione.
Clopidogrel in ACS: Overview Investigator, TIMI Study Group Associate Physician, Cardiovascular Division, BWH Assistant Professor of Medicine, Harvard.

Clopidogrel in ACS: Overview Investigator, TIMI Study Group Associate Physician, Cardiovascular Division, BWH Assistant Professor of Medicine, Harvard.
Anticoagulation and Thrombosis Management

Anticoagulation and Thrombosis Management
  Warfarin Dabigatran Rivaroxaban Apixaban Edoxaban Target

  Warfarin Dabigatran Rivaroxaban Apixaban Edoxaban Target
Supervisor: Vs 余垣斌 Presenter: CR 周益聖. INTRODUCTION.

Supervisor: Vs 余垣斌 Presenter: CR 周益聖. INTRODUCTION.
John H. Alexander, MD, MHS Associate Professor of Medicine Director, Cardiovascular Research Duke Clinical Research Institute Duke Medicine Update on antithrombotics.

John H. Alexander, MD, MHS Associate Professor of Medicine Director, Cardiovascular Research Duke Clinical Research Institute Duke Medicine Update on antithrombotics.
Stroke Prevention Using the Oral Direct Thrombin Inhibitor Ximelagatran in Patients With Nonvalvular Atrial Fibrillation SPORTIF V Trial Presented at American.

Stroke Prevention Using the Oral Direct Thrombin Inhibitor Ximelagatran in Patients With Nonvalvular Atrial Fibrillation SPORTIF V Trial Presented at American.
ARISTOTLE Objectives Primary: test for noninferiority of apixaban, a novel oral direct factor Xa inhibitor, versus warfarin Secondary: test for superiority.

ARISTOTLE Objectives Primary: test for noninferiority of apixaban, a novel oral direct factor Xa inhibitor, versus warfarin Secondary: test for superiority.
A Randomized Trial of Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism Schulman S et al. Proc ASH 2011;Abstract 205.

A Randomized Trial of Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism Schulman S et al. Proc ASH 2011;Abstract 205.
Dabigatran Etexilate is Effective and Safe for the Extended Prevention of Venous Thromboembolism Following Total Hip Replacement Eriksson BI, Dahl OE,

Dabigatran Etexilate is Effective and Safe for the Extended Prevention of Venous Thromboembolism Following Total Hip Replacement Eriksson BI, Dahl OE,
¨ 8 European countries, 48 centres Stent implantation Double-blind randomisation n = 1005 Clopidogrel 300mg od Aspirin 325mg od Clopidogrel 75mg od Aspirin.

¨ 8 European countries, 48 centres Stent implantation Double-blind randomisation n = 1005 Clopidogrel 300mg od Aspirin 325mg od Clopidogrel 75mg od Aspirin.
WarfarinApixaban Primary outcome: major/clinically relevant bleeding (through 6 months) Secondary objective: Death, MI, stroke, stent thrombosis Randomize.

WarfarinApixaban Primary outcome: major/clinically relevant bleeding (through 6 months) Secondary objective: Death, MI, stroke, stent thrombosis Randomize.
Date of download: 6/27/2016 Copyright © The American College of Cardiology. All rights reserved. From: Use and Outcomes of Triple Therapy Among Older Patients.

Date of download: 6/27/2016 Copyright © The American College of Cardiology. All rights reserved. From: Use and Outcomes of Triple Therapy Among Older Patients.

Similar presentations

Ads by Google